Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Noninvasive Tests for NASH

Source: Hot Topics in NASH: Current Controversies and New Developments in Fatty Liver Disease
Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests for NASH.
Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC
Released: July 7, 2020

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:

  • Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2
  • Assessment of therapeutic response
  • Assessment of long-term patient outcomes

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/noninvasive-testing-now-and-in-the-future/slideset 

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics 

Acknowledgements

Provided by the American Gastroenterology Association.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Expert insight on the burden and impact of HBV infection, as well as strategies to overcome barriers to vaccination, from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 22, 2022 Expired: March 21, 2023

Expert insights on emerging NAFLD/NASH treatments from Dr. Stephen Harrison and Clinical Care Options (CCO)

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Downloadable slides from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: September 9, 2021

Video from CCO and Dr. Stephen Harrison highlighting take-home points about pathogenesis, risk, and treatment of NAFLD/NASH from the NASH Core Curriculum

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 9, 2021 Expired: September 8, 2022
Prevalence and Pathogenesis
Risk Factors and Screening
Current Management
Emerging Agents

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings